Finance
French finance minister criticises Sanofi's $20 billion USA investment decision
Published by Global Banking & Finance Review®
Posted on May 15, 2025
1 min readLast updated: January 23, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on May 15, 2025
1 min readLast updated: January 23, 2026
Sanofi's $20 billion investment in the USA by 2030 faces criticism from France's finance minister, highlighting a push for more domestic investments.
PARIS (Reuters) -France's finance minister criticised on Thursday a decision by French drugmaker Sanofi to invest at least $20 billion in the United States through to 2030, as France aims to get more companies investing in the country rather than abroad.
"It's clear it was not something that was nice to see and it was an unpleasant announcement," finance minister Eric Lombard told BFM Business TV.
"It sends out a bad signal," he also said, adding he hoped Sanofi would continue to invest in France.
The French drugmaker, one of the world's largest vaccine makers and a leader in anti-inflammatory drugs, said on Wednesday that it planned to expand its U.S. manufacturing capacity through direct investments in Sanofi sites, and partnerships with other domestic manufacturers.
Sanofi's decision was the latest one from leading drugmakers which have been expanding their U.S. presence in response to President Donald Trump's trade policies.
(Reporting by Sudip Kar-Gupta;Editing by Benoit Van Overstraeten)
The main topic is Sanofi's decision to invest $20 billion in the USA and the criticism it received from the French finance minister.
Sanofi plans to expand its US manufacturing capacity, influenced by US trade policies.
France's finance minister, Eric Lombard, criticized the decision.
Explore more articles in the Finance category
